SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

吉西他滨 医学 内科学 危险系数 顺铂 胃肠病学 肿瘤科 化疗 胆道 胰腺癌 泌尿科 癌症 置信区间
作者
Rachna T. Shroff,Gentry Teng King,Sarah Colby,Aaron J. Scott,Mitesh J. Borad,Laura W. Goff,Khalid Matin,Amit Mahipal,Aparna Kalyan,Milind Javle,Imane El Dika,Benjamin Tan,P. Cheema,Anuj Patel,Renuka Iyer,Robin Kate Kelley,Jaykumar Thumar,Anthony B. El-Khoueiry,Katherine A. Guthrie,E. Gabriela Chiorean,Howard S. Höchster,Philip A. Philip
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
被引量:1
标识
DOI:10.1200/jco-24-01383
摘要

PURPOSE SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs). METHODS Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m 2 , cisplatin 25 mg/m 2 , and nab-paclitaxel 100 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m 2 and cisplatin 25 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle). RESULTS Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC. There was no significant difference in overall survival (OS) between GAP versus GC. Median OS with GAP was 14.0 months (95% CI, 12.4 to 16.1) and 13.6 months with GC (95% CI, 9.7 to 16.6); hazard ratio (HR), 0.91 (95% CI, 0.72 to 1.14); P = .41. Median progression-free survival (PFS) was similar between groups with median PFS for GAP being 7.5 months (95% CI, 6.4 to 8.5) versus 6.3 months for GC (95% CI, 4.4 to 8.2); HR, 0.89 (95% CI, 0.71 to 1.12); P = .32. In exploratory subset analyses, the OS and PFS benefits of GAP versus GC treatment were greater in locally advanced disease compared with metastatic disease, although not statistically significant (interaction P = .14 for OS and P = .17 for PFS). Moreover, GAP versus GC showed greater improvement in PFS among participants with GBC than those with ICC or ECC (interaction P = .01), but not OS (interaction P = .28). CONCLUSION The addition of a taxane in the GAP regimen to the standard gemcitabine-cisplatin regimen did not improve OS in newly diagnosed BTC. More toxicity was encountered with GAP versus GC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王汉韬完成签到,获得积分20
刚刚
奥一奥完成签到,获得积分10
1秒前
欣喜沛芹发布了新的文献求助10
1秒前
纾缓发布了新的文献求助10
1秒前
WW完成签到,获得积分10
1秒前
zlttt完成签到,获得积分20
2秒前
852应助momo采纳,获得10
3秒前
此间少年发布了新的文献求助10
3秒前
王汉韬发布了新的文献求助10
3秒前
哈哈完成签到 ,获得积分10
4秒前
英俊的铭应助xn201120采纳,获得10
4秒前
闾丘惜萱完成签到,获得积分10
4秒前
baonali发布了新的文献求助10
6秒前
yyyhhh完成签到,获得积分10
8秒前
ZH完成签到 ,获得积分10
12秒前
12秒前
12秒前
ll完成签到,获得积分10
13秒前
纾缓完成签到,获得积分10
15秒前
潘善若发布了新的文献求助10
15秒前
20秒前
Willy完成签到,获得积分10
21秒前
22秒前
大模型应助史念薇采纳,获得10
22秒前
22秒前
科研通AI2S应助xn201120采纳,获得10
22秒前
24秒前
潘善若发布了新的文献求助10
24秒前
万能图书馆应助GooJohn采纳,获得10
25秒前
梨花酒完成签到,获得积分10
25秒前
阿里山完成签到,获得积分10
26秒前
momo发布了新的文献求助10
27秒前
Amai完成签到,获得积分10
29秒前
Panjiao完成签到 ,获得积分10
33秒前
33秒前
34秒前
35秒前
Owen应助xiaohu采纳,获得10
35秒前
潘善若发布了新的文献求助10
38秒前
Fengliguantou发布了新的文献求助10
39秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136